Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hong-Hu Zhu

Showing results (41-50 of 120) with videos related to

Pageof 12
Sort By:
Zhongguo Shi Yan Xue Ye Xue Za Zhi|September 4, 2013
Expression of PML-RARα is up-regulated during ATRA and arsenics combined induction without influence on long-term prognosis of acute promyelocytic leukemiaHong-Hu Zhu, Ya-Zhen Qin, Yue-Yun Lai, et al.
Annals of Hematology|May 5, 2023
CAG (cytarabine, aclarubicin and granulocyte colony-stimulating factor) regimen for core binding factor acute myeloid leukaemia with measurable residual diseaseYao-Jia Shen, Yi Zhang, Jie Chang, et al.
Annals of Hematology|June 29, 2011
Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantationXiao-Su Zhao, Yan-Rong Liu, Hong-Hu Zhu, et al.
Clinical and Translational Science|September 17, 2024
Paired comparisons of venetoclax concentration in cerebrospinal fluid, bone marrow, and plasma in acute leukemia patientsYuan Jian, Feifei Han, Ying Zhu, et al.
Beijing Da Xue Xue Bao. Yi Xue Ban = Journal of Peking University. Health Sciences|June 17, 2006
[Mechanism of tetra-arsenic tetra-sulfide in inducing apoptosis of acute promyelocytic leukemia cells]Zhi-ping Teng, Ping Zhang, Hong-hu Zhu, et al.
Theranostics|September 15, 2020
PML-RARα interaction with TRIB3 impedes PPARγ/RXR function and triggers dyslipidemia in acute promyelocytic leukemiaKe Li, Feng Wang, Zhao-Na Yang, et al.
Medicine|January 15, 2016
Combination of White Blood Cell Count at Presentation With Molecular Response at 3 Months Better Predicts Deep Molecular Responses to Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia PatientsYa-Zhen Qin, Qian Jiang, Hao Jiang, et al.
Genomics, Proteomics & Bioinformatics|April 29, 2025
Integrated Computational and Functional Screening Identify G9a Inhibitors for SETD2-Mutant LeukemiaYa Zhang, Mengfang Xia, Zhenyi Yi, et al.
Leukemia & Lymphoma|February 26, 2013
Cytarabine, aclarubicin and granulocyte colony-stimulating factor regimen represents an effective and safe salvage regimen for patients with acute myeloid leukemia refractory to first course of induction chemotherapyHong-Hu Zhu, Hao Jiang, Bin Jiang, et al.
Hematology (Amsterdam, Netherlands)|November 28, 2024
First case of acute promyelocytic leukemia with TFG-RARA achieved complete remission treated with venetoclax and all-trans retinoic acidLi Zhu, Ting Shi, Yi Liu, et al.
Pageof 12

Showing results (41-50 of 120) with videos related to

Sort By:
Pageof 12
Zhongguo Shi Yan Xue Ye Xue Za Zhi|September 4, 2013
Expression of PML-RARα is up-regulated during ATRA and arsenics combined induction without influence on long-term prognosis of acute promyelocytic leukemiaHong-Hu Zhu, Ya-Zhen Qin, Yue-Yun Lai, et al.
Annals of Hematology|May 5, 2023
CAG (cytarabine, aclarubicin and granulocyte colony-stimulating factor) regimen for core binding factor acute myeloid leukaemia with measurable residual diseaseYao-Jia Shen, Yi Zhang, Jie Chang, et al.
Annals of Hematology|June 29, 2011
Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantationXiao-Su Zhao, Yan-Rong Liu, Hong-Hu Zhu, et al.
Clinical and Translational Science|September 17, 2024
Paired comparisons of venetoclax concentration in cerebrospinal fluid, bone marrow, and plasma in acute leukemia patientsYuan Jian, Feifei Han, Ying Zhu, et al.
Beijing Da Xue Xue Bao. Yi Xue Ban = Journal of Peking University. Health Sciences|June 17, 2006
[Mechanism of tetra-arsenic tetra-sulfide in inducing apoptosis of acute promyelocytic leukemia cells]Zhi-ping Teng, Ping Zhang, Hong-hu Zhu, et al.
Theranostics|September 15, 2020
PML-RARα interaction with TRIB3 impedes PPARγ/RXR function and triggers dyslipidemia in acute promyelocytic leukemiaKe Li, Feng Wang, Zhao-Na Yang, et al.
Medicine|January 15, 2016
Combination of White Blood Cell Count at Presentation With Molecular Response at 3 Months Better Predicts Deep Molecular Responses to Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia PatientsYa-Zhen Qin, Qian Jiang, Hao Jiang, et al.
Genomics, Proteomics & Bioinformatics|April 29, 2025
Integrated Computational and Functional Screening Identify G9a Inhibitors for SETD2-Mutant LeukemiaYa Zhang, Mengfang Xia, Zhenyi Yi, et al.
Leukemia & Lymphoma|February 26, 2013
Cytarabine, aclarubicin and granulocyte colony-stimulating factor regimen represents an effective and safe salvage regimen for patients with acute myeloid leukemia refractory to first course of induction chemotherapyHong-Hu Zhu, Hao Jiang, Bin Jiang, et al.
Hematology (Amsterdam, Netherlands)|November 28, 2024
First case of acute promyelocytic leukemia with TFG-RARA achieved complete remission treated with venetoclax and all-trans retinoic acidLi Zhu, Ting Shi, Yi Liu, et al.
Pageof 12